English
Regional settings| Spread | 0.05 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.61 |
| Open | 0.61 |
| 1-Year Change | -84.03% |
| Day's Range | 0.58 - 0.62 |
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.
BRIEF: For the nine months ended 30 September 2021, Petros Pharmaceuticals Inc revenues totaled $8.7M. Net loss totaled to $801K.
